Abbott Laboratories' Established Pharmaceuticals Division reported second-quarter 2026 sales growth of 8.4% on a reported basis and 8.7% on a comparable basis, driven by strong performance in emerging markets. Key Emerging Markets delivered 10.7% comparable sales growth, with double-digit gains across several countries in Latin America and Asia Pacific. The company is expanding its biosimilar pipeline to broaden the division's product portfolio and sustain high-single-digit sales growth over the long term. Abbott shares have fallen 14.3% over the past year, and the stock currently carries a Zacks Rank #3 (Hold).
Abbott LaboratoriesEPD reports strong emerging-market sales growth and biosimilar pipeline expansion.
Boston Scientific Corp
Medtronic PLC